- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about IPSEY
Recent news which mentions IPSEY
From Benzinga
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
From InvestorPlace
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
From Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
June 30, 2023
From Benzinga
From Benzinga
From Benzinga
Why These Two Biotech Stocks Blasted Higher This Week
January 13, 2023
From Motley Fool
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
January 09, 2023
From Motley Fool
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
January 09, 2023
From Benzinga
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
From Benzinga
Why Merrimack Shares Are Surging Over 200% Today?
November 09, 2022
From Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
From Benzinga
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
September 19, 2022
From Benzinga
From Benzinga
From Benzinga
Why Adaptimmune Therapeutics Stock Is Popping Today
June 27, 2022
From Motley Fool
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
June 27, 2022
From Benzinga
Why Epizyme Stock Is Soaring Today
June 27, 2022
From Motley Fool
From Benzinga
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
June 27, 2022
From Benzinga
From Motley Fool
From Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
May 03, 2022
From Benzinga
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
From Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
From Benzinga
From Benzinga
From Benzinga
GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters
December 17, 2021
From InvestorPlace
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.